First treatment for the disorder ever approved.
Last week, the Food and Drug Administration (FDA) approved a treatment for eosinophilic esophagitis for the first time. The disorder causes a type of white blood cell to become prolific in the esophagus, causing the area to become inflamed and cause difficulty swallowing and eating. The approved treatment, Dupixent, is a monoclonal antibody that stops those white blood cells from causing inflammation.
“As researchers and clinicians have gained knowledge about eosinophilic esophagitis in recent years, more cases of the disorder have been recognized and diagnosed in the U.S.,” said Dr. Jessica Lee, director of the Division of Gastroenterology in the FDA’s Center for Drug Evaluation and Research. “Today’s approval will fulfill an important unmet need for the increasing number of patients with eosinophilic esophagitis.”
As the Lord Leads, Pray with Us…
- For FDA Commissioner Califf as he oversees the approval and authorization of treatments and therapies.
- For FDA officials as they weigh the benefits and downsides of medical interventions.
- For U.S. scientists and researchers evaluating the effectiveness of medications and pharmaceuticals.
Sources: Food and Drug Administration
